Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple nerve block cut pneumonia risk after rib fractures?

NCT ID NCT07032766

Knowledge-focused Sponsor: Albert Einstein College of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at whether a nerve block called the serratus anterior plane block (SAPB) can improve outcomes for adults with multiple rib fractures on one side. Researchers will compare patients who receive this block within 24 hours of injury to those who get standard opioid pain relief. They will track rates of pneumonia, length of hospital stay, need for intensive care, and survival to see if the block offers meaningful benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
serratus anterior plane block (SAPB), a nerve block procedure
What this could lead to
If effective, this nerve block could become a standard early treatment for rib fractures, potentially lowering pneumonia rates and shortening hospital stays.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by differences between groups. The block's benefit is uncertain and depends on physician availability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include a cohort of patients presenting within 24 hours of injury with two or more unilateral, anterior or lateral rib fractures requiring opioid analgesia that would be admitted to the trauma service at a single urban level 1 trauma center. The authors anticipate recruitment of 200 participants over the course of a study duration of 1 year.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center * Presenting within 24 hours of injury * Patient with 2 or more unilateral, anterior or lateral rib fractures * Able to provide consent (patient or health care proxy) * Clinical team believes the patient will require inpatient admission at the time of enrollment Exclusion Criteria: * Patients in traumatic arrest or hemodynamic instability * Patient expected to be discharged from the hospital within 24 hours * Prisoner * Pregnancy * Children less than 18 years of age * The patient is known or is suspected to be allergic to anesthetic * Significant pain from another traumatic and distracting injury * Patients without the ability to consent (or no health care proxy to consent) * Patients with bilateral or posterior rib fractures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Rib Fractures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain management Rib fracture multiple Serratus anterior plane block

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jacobi Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.